A157 THE THRESHOLD FOR INFLIXIMAB TROUGH LEVELS LEADING TO DOSE ESCALATION DIFFERS BETWEEN CROHN’S DISEASE AND ULCERATIVE COLITIS

BACKGROUND: Therapeutic drug monitoring (TDM) of infliximab (IFX) provides an objective measure that allows physicians to optimize the dose for patients on biologic therapies and potentially reduce loss of response (LOR). The currently accepted therapeutic range is 3 – 7 μg/mL. With the potential fo...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Can Assoc Gastroenterol
Main Authors: Cookson, T A, Fedorak, R, Halloran, B P, Dieleman, L A, Wong, K, Huang, V, Peerani, F, Kroeker, K I
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2018
Assuntos:
Paper Sessions
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6508180/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jcag/gwy009.157
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados